A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Cilostazol

Phosphodiesterase 3 Inhibitor class · 5 generic manufacturers · 10 ANDAs filed at FDA.

First FDA approval2004-11-23
Generic availableYes · 5 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$26.1M in CY2024 Part D spend1.2M claims · 363K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.109/unit
11 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.120
Across all dosage forms in distribution.
Highest NADAC
$0.129
Range is tight.
Plans with PA
2 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Cilostazol used for?

Cilostazol is a Phosphodiesterase 3 Inhibitor medication tracked in Medicare Part D.

Is there a generic for Cilostazol?

Yes. 10 ANDAs filed at FDA, 5 generic manufacturers currently shipping.

How much does my plan pay for Cilostazol?

Across 329 Part D plans, Cilostazol averages $0.120/unit (NADAC). Lowest available: $0.109/unit. Highest in distribution: $0.129/unit.

Is Cilostazol on the FDA shortage list?

No. Cilostazol is not currently on the FDA Drug Shortage Database.

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Phosphodiesterase 3 Inhibitor2 alternatives in D1
01
Ensifentrine
Brand: Ohtuvayre
Lowest NADAC
0Generic mfrs
$328,175CY24 Part D spend
Compare →
02
Milrinone
Phosphodiesterase 3 Inhibitor
Lowest NADAC
10Generic mfrs
CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (11 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.